Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2013 Financial Results

  Opexa Therapeutics Announces News Release and Conference Call Schedule to
  Discuss First Quarter 2013 Financial Results

Business Wire

THE WOODLANDS, Texas -- May 10, 2013

Opexa Therapeutics, Inc. (NASDAQ: OPXA), a leader in developing a patient
specific T-cell immunotherapy for multiple sclerosis (MS), today announced
that the company will report financial results for the three months ended
March 31, 2013, before the opening of trading on Tuesday, May 14^th. The
company will also conduct a conference call and webcast to discuss financial
results and provide a corporate update at 8 A.M. Eastern Time on Tuesday, May
14^th.

Conference Call and Webcast Details

To listen to the conference call, dial in approximately ten minutes before the
scheduled 8 AM time to (253) 237-1170 or toll free at (877) 372-0867. Please
reference conference ID # 70924987 while dialing into the call.

A live webcast of the call can also be accessed via the webcast link on our
website (www.opexatherapeutics.com) or by going to the following URL:

http://investor.shareholder.com/media/eventdetail.cfm?eventid=129946&CompanyID=OPXA&e=1&mediaKey=52AF10A2390CE08BC8D2847172A3B20C

There will be a brief Question & Answer session following management
commentary. Share holders and interested parties are highly encouraged to
submit questions in advance by e-mail addressed to
kradhakrishnan@opexatherapeutics.com.

About Opexa

Opexa’s mission is to lead the field of precision immunotherapy by aligning
the interests of patients, employees and share holders. The Company’s leading
therapy candidate, Tcelna™, is a personalized T-cell immunotherapy that is in
a Phase IIb clinical development program (the Abili-T trial) for the treatment
of Secondary Progressive Multiple Sclerosis. Tcelna is derived from T-cells
isolated from the patient’s peripheral blood, expanded ex vivo, and
reintroduced into the patients via subcutaneous injections. This process
triggers a potent immune response against specific subsets of autoreactive
T-cells known to attack myelin.

For more information visit the Opexa Therapeutics website at
www.opexatherapeutics.com

About Multiple Sclerosis (MS)

Multiple Sclerosis is a chronic, inflammatory condition of the central nervous
system and is the most common, non-traumatic, disabling neurological disease
in young adults. It is estimated that approximately two million people have MS
worldwide.

While symptoms can vary, the most common symptoms of MS include blurred
vision, numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common.

About Tcelna

Tcelna is a potential personalized therapy that is under development to be
specifically tailored to each patient's disease profile. Tcelna is
manufactured using ImmPath™, Opexa's proprietary method for the production of
a patient-specific T-cell immunotherapy, which encompasses the collection of
blood from the MS patient, isolation of peripheral blood mononuclear cells,
generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised
against selected peptides from myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the
return of these expanded, irradiated T-cells back to the patient. These
attenuated T-cells are reintroduced into the patient via subcutaneous
injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna. Named Abili-T, the
trial is a randomized, double-blind, placebo-controlled clinical study in
patients who demonstrate evidence of disease progression without associated
relapses. The trial is expected to enroll 180 patients at approximately 30
leading clinical sites in the U.S. and Canada with each patient receiving two
annual courses of Tcelna treatment consisting of five subcutaneous injections
per year. The trial’s primary efficacy outcome is the percentage of brain
volume change (atrophy) at 24 months. Study investigators will also measure
several important secondary outcomes commonly associated with MS, including
disease progression as measured by the Expanded Disability Status Scale
(EDSS), annualized relapse rate and changes in disability as measured by EDSS
and the MS Functional Composite.

Contact:

Company
Karthik Radhakrishnan
Opexa Therapeutics, Inc.
Chief Financial Officer
281-775-0600
kradhakrishnan@opexatherapeutics.com
or
Investor Relations
Adam Cutler
The Trout Group
Adam Cutler
646-378-2936
opexa@troutgroup.com
 
Press spacebar to pause and continue. Press esc to stop.